We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us

Download Mobile App




Events

ATTENTION: Due to the COVID-19 PANDEMIC, many events are being rescheduled for a later date, converted into virtual venues, or altogether cancelled. Please check with the event organizer or website prior to planning for any forthcoming event.
30 Jan 2023 - 02 Feb 2023

MR Imaging Technique Promises More Reliable Cancer Screening and Diagnosis

By MedImaging International staff writers
Posted on 13 Jun 2016
Print article
Image: The EU-funded Horizon 2020 GlucoCEST Imaging in Neoplastic Tumours Project (Photo courtesy of GLINT 2016).
Image: The EU-funded Horizon 2020 GlucoCEST Imaging in Neoplastic Tumours Project (Photo courtesy of GLINT 2016).
A project to develop a novel advanced medical imaging technology is intended to enable earlier detection of cancer, increase survival rates, and allow for a patients’ full recovery.

The new imaging technology is intended to provide more reliable and less invasive cancer diagnosis based on a novel Magnetic Resonance Imaging (MRI) technique that could lead to game-changing diagnostic tools for cancer imaging, and enable personalized cancer treatment.

The European Union (EU)-funded GlucoCEST Imaging of Neoplastic Tumours (GLINT) project began in January 2016, and makes use of a technique called glucose-based Chemical Exchange Saturation Transfer (glucoCEST). The technique can be used to detect the massive native glucose uptake in tumors as they grow. Previously such glucose measurements had to be made using a radio-labeled glucose imaging agent, and Positron Emission Tomography (PET) imaging. The new technique does not require contrast agents and enables closer treatment monitoring.

Scientific Coordinator of GLINT, and inventor of the glucoCEST method Professor Xavier Golay, University College London (London, UK), said, “GLINT offers for the first time a possibility to bring to the clinics a much-touted new imaging technique, allowing to directly image by MRI native, non-labeled glucose the way PET does it using the expensive radio-labeled sugar analogue fluorodeoxyglucose (FDG). This represents among others a huge hope for pediatric patients and for everyone required to undergo continuous surveillance of cancer progression. It also carries the hope to reduce or at least significantly limit the costs of diagnostic cancer imaging.”

Related Links:
University College London


Print article
CIRS -  MIRION
Radcal

Channels

Ultrasound

view channel
Image: A combination of ultrasound and nanobubbles allows cancerous tumors to be destroyed without surgery (Photo courtesy of Tel Aviv University)

Ultrasound Combined With Nanobubbles Enables Removal of Tumors Without Surgery

The prevalent method of cancer treatment is surgical removal of the tumor, in combination with complementary treatments such as chemotherapy and immunotherapy. Therapeutic ultrasound to destroy the cancerous... Read more

General/Advanced Imaging

view channel
Image: AI tool predicts reduced blood flow to the heart (Photo courtesy of Pexels)

AI Tool Uses CT Scans to Identify Patients at Risk of Reduced Blood Flow to the Heart

Blockages of the coronary arteries typically occur due to the buildup of fatty plaques. This may restrict blood flow to the heart, causing chest pain, heart attacks, or even death. Identifying which arteries... Read more

Imaging IT

view channel
Image: The new Medical Imaging Suite makes healthcare imaging data more accessible, interoperable and useful (Photo courtesy of Google Cloud)

New Google Cloud Medical Imaging Suite Makes Imaging Healthcare Data More Accessible

Medical imaging is a critical tool used to diagnose patients, and there are billions of medical images scanned globally each year. Imaging data accounts for about 90% of all healthcare data1 and, until... Read more
Copyright © 2000-2022 Globetech Media. All rights reserved.